Monographie - Heparin sodium

Poslední aktualizace :
19/11/2024

Heparin sodium

Chemický vzorec

Obchodní název

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Arapin	Chile
Ateroclar	Itálie
Clarisco	Itálie
Epsoclar	Itálie
Hepaflex	Finsko, Norsko
Hepamax	Chile, Ekvádor, Kolumbie
Heparin	Dánsko, Finsko, Jihoafrická republika, Jugoslávie, Kanada, MaÔarsko, Nizozemsko, Norsko, Rakousko, rusky, Švédsko, Švýcarsko, Thajsko, Turecko, USA, Velká Británie, ÿecko
Heparine	Belgie, Francie
Heparinised	Austrálie
Heparstad	NÏmecko
Liquemin	Švýcarsko, Turecko
Liquemine	BrazÌlie
Monoparin	Saúdská Arábie
Normoparin	Itálie
Nuparin	Ekvádor
Pharepa	Itálie
Riveparin	Argentina
Sobrius	Argentina, Ekvádor
Thrombophob	NÏmecko

Odkazy : Heparin sodium

	typ	uveřejnění
3	noviny	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
36	noviny	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
59	noviny	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
66	noviny	Avelar MA, Walker SE. Stability and compatibility of reconstituted hydromorphone with potassium chloride or heparin. Can J Hosp Pharm 1996 ; 49: 140-145.
73	noviny	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	noviny	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	noviny	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	noviny	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
92	noviny	Lee CY, Mauro VF, Alexander KS. Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 606-608.
93	noviny	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	noviny	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
129	noviny	Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126.
132	noviny	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
150	noviny	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
156	noviny	Barberi-Hayob M, Merlin JL, Vigneron M, Conroy T. Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions. Anticancer Drugs 1995 ; 6: 163-164.
163	noviny	Sewell GJ, Allsopp M, Collinson MP, Tyrrell C, Prentice AJ, Copplestone JA. Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens. J Clin Pharm Ther 1994 ; 19: 127-133.
169	noviny	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
174	noviny	Schaaf LJ, Robinson DH, Vogel GJ, Wulf BG, Drda KD, Moses JO. Stability of esmolol hydrochloride in the presence of aminophylline, bretylium tosylate, heparin sodium, and procainamide hydrochloride. Am J Hosp Pharm 1990 ; 47: 1567-1571.
182	noviny	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	noviny	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
187	noviny	Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS. Stability of flumazenil with selected drugs in 5% dextrose injection. Am J Hosp Pharm 1993 ; 50: 1907-1912.
198	noviny	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
214	noviny	Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ. Stability of ranitidine hydrochloride with eight medications in intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 1606-1610.
215	noviny	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
240	noviny	Lam XM, Ward CA, de C du M?e CPR. Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy. Am J Health-Syst Pharm 1995 ; 52: 1904-1909.
244	noviny	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	noviny	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	noviny	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	noviny	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	noviny	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
257	noviny	Hunt-Fugate AK, Hennessey CK, Kazarian CM. Stability of fluconazole in injectable solutions. Am J Hosp Pharm 1993 ; 50: 1186-1187.
266	noviny	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
288	noviny	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
289	noviny	Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707.
295	noviny	Yamashita SK, Walker SE, Choudhury T, Iazzetta J. Compatibility of selected critical care drugs during Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299	noviny	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	noviny	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	noviny	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	noviny	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
314	noviny	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
315	noviny	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
317	noviny	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
334	noviny	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	noviny	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	noviny	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	noviny	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
341	noviny	Baker DE, Yost GS, Craig VL, Campbell RK. Compatibility of heparin sodium and morphine sulfate. Am J Hosp Pharm 1985 ; 42: 1352-1355.
377	noviny	Pereira-Rosario R, Utamura T, Perrin JH. Interaction of heparin sodium and dopamine hydrochloride in admixtures studied by microcalorimetry. Am J Hosp Pharm 1988 ; 45: 1350-1352.
384	noviny	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
386	noviny	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
396	noviny	Chilvers MR, Lysne JM. Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications. Am J Hosp Pharm 1989 ; 46: 2057-2058.
397	noviny	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
398	noviny	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
402	noviny	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
406	noviny	Smythe MA, Patel MA, Gasloli RA. Visual compatibility of narcotic analgesics with selected intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 819-820.
479	noviny	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	noviny	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	noviny	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	noviny	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
617	noviny	Solomon DA, Nasinnyk KK. Compatibility of haloperidol lactate and heparin sodium. Am J Hosp Pharm 1982 ; 39: 843-844.
660	noviny	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
738	noviny	Gardella LA, Kesler H, Amann A, Carter JE. Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives. Am J Hosp Pharm 1978 ; 35: 581-584.
763	noviny	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
791	noviny	Hensrud DD, Buritt MF, Hall LG. Stability of heparin anticoagulant activity over time in parenteral nutrition solutions. JPEN 1996 ; 20: 219-220.
813	noviny	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
860	noviny	Nelson RW, Young R, Lamnin M. Visual incompatibility of dacarbazine and heparin. Am J Hosp Pharm 1987 ; 44: 2028.
874	noviny	Stiles ML, Allen LV, Mc Laury HJ. Stability of two concentrations of heparin sodium prefilled in CADD-Micro pump syringes. Int J Pharm Compound 1997 ; 1: 433-434.
891	noviny	Matsuura G. Visual compatibility of sargramostim (GM-CSF) during simulated Y-site administration with selected agents. Hosp Pharm 1992 ; 27: 200, 202, 209.
895	noviny	Yao JDC, Arkin CF, Karchmer AW. Vancomycin stability in heparin and total parenteral nutrition solutions: novel approach to therapy of central venous catheter-related infections. JPEN 1992 ; 16: 268-274.
905	noviny	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	noviny	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	noviny	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
963	noviny	Schaaf LJ, Tremel LC, Wulf BG, Vernon KK. Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside. J Clin Pharm Ther 1990 ; 15: 371-376.
1022	noviny	Hutchinson SMW. Heparin and aminoglycosides instability. Drug Intell Clin Pharm 1986 ; 20: 886.
1041	noviny	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1057	noviny	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1058	noviny	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1067	noviny	Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.
1070	noviny	Balthasar JP. Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium. Am J Health-Syst Pharm 1999 ; 56: 1891.
1072	noviny	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1084	noviny	Raupp P, von Kriek R, Schmidt E, Pfahl HG, G?nther O. Incompatibility between fat emulsion and calcium plus heparin in parenteral nutrition of premature babies. Lancet 1988 ; 1(8587): 700.
1085	noviny	Irving HD, Burbridge BE. Incompatibility of contrast agents with intravascular medications. Radiology 1989 ; 173: 91-92.
1135	noviny	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1183	noviny	Tunbridge LJ, Lloyd JV, Penhall RK, Wise AL, Maloney T. Stability of diluted heparin sodium stored in plastic syringes. Am J Hosp Pharm 1981 ; 38: 1001-1004.
1228	noviny	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
1232	noviny	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1234	noviny	Parkinson R, Wilson JV, Ross M, Denyer SP. Stability of low-dosage heparin in pre-filled syringes. Br J Pharm Pract 1989 ; 11: 34-36.
1258	noviny	Tyler LS, Rehder TL, Davis RB. Effect of gentamicin on heparin activity. Am J Hosp Pharm 1981 ; 38: 537-540.
1289	noviny	Hecq JD, Evrard JM, Gillet P, Grosdent N. Etude de stabilité visuelle du chlorhydrate de chlorpromazine, du chlorure de potassium, de la furosémide et de l’héparine sodique en perfusion continue. Pharmakon 1998 ; 116: 145-148.
1291	noviny	Wright A, Hecker J. Long term stability of heparin in dextrose-saline intravenous fluids. Int J Pharm Pract 1995 ; 3: 253-255.
1315	noviny	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1352	noviny	Hasegawa GR, Eder JF. Dobutamine-heparin mixture inadvisable. Am J Hosp Pharm 1984 ; 41: 2588-2589.
1391	noviny	Vanstone GL. Is heparin always compatible with TPN and fat emulsion admixtures? Can J Hosp Pharm 1998 ; 51: 271-272.
1393	noviny	Lyall D, Blythe J. Ciprofloxacin lactate infusion. Pharm J 1987 ; 238: 290.
1410	noviny	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1414	noviny	Mayer JLR, Pascale VJ, Clyne LP, Malkus H, Santos FS, van Hoff J. Stability of low-dose vancomycin hydrochloride in heparin sodium 100 UI / ml. J Pharm Technol 1999 ; 15: 13-17.
1415	noviny	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1420	noviny	Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M. Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration. J Clin Pharm Ther 1999 ; 24: 125-132.
1423	noviny	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1468	noviny	Sautou V, Chopineau J, Gremeau I, Chevrier R, Bruneaux F. Compatibility with medical plastics and stability of continuously and simultaneously infused isosorbide dinitrate and heparin. Int J Pharm 1994 ; 107: 111-119.
1490	noviny	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1496	noviny	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1506	noviny	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1508	noviny	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1512	Laboratoř	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1625	noviny	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	noviny	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1699	noviny	Plaas S, Heck C, Kubrich M. Mischbarkeit von serotonin-antagonisten mit dexamethason und heparin. Krankenhauspharmazie 2000 ; 21: 107-109.
1703	noviny	Schuster F, Bernard R. Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln. Krankenhauspharmazie 1995 ; 16: 101-103.
1712	noviny	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	noviny	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	noviny	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	noviny	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1801	noviny	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1802	noviny	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803	noviny	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1822	noviny	Trissel LA, Seanz C. Physical compatibility of antithymocyte globulin (rabbit) with heparin sodium and hydrocortisone sodium succinate. Am J Health-Syst Pharm 2003 ; 60: 1650-1652.
1868	noviny	Husson E, Crauste-Manciet S, Hadj-Salah E, ,Segier JC, Broissard D. Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange. Nutr Clin Metab 2003 ; 17: 8-14.
1906	noviny	McQuade MS, Van Nostrand V, Shariter J, Kanike JD, Forsyth RJ. Stability and compatibility of reconstituted ertapenem with commonly used iv infusion and coinfusion solutions. Am J Health-Syst Pharm 2004 ; 61: 38-45.
1925	noviny	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1937	noviny	Lai JJ, Brodeur SK. Physical and chemical stability of daptomycin with nine medications. Ann Pharmacotherapy 2004 ; 38: 1612-1616.
1953	noviny	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1979	noviny	Wu CC, Wang DP, Wong CY, Lin YF. Stability of cefazolin in heparinized and nonheparinized peritoneal dialysis solutions. Am J Health-Syst Pharm 2002 ; 59: 1537-1538.
1982	noviny	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2037	noviny	Robinson JL, Tawfik G, Saxinger L, Stang L, Etches W, Lee B. Stability of heparin and physical compatibility of heparin/antibiotic solutions ... J Antimicrob Chemother 2005 ; 56: 951-953.
2057	noviny	Droste JC, Jeraj HA, MacDonald A, Farrington K. Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. J Antimicrob Chemother 2003 ; 51: 849-855.
2087	noviny	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	noviny	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2100	noviny	Gervas S, Gosalbez F. Estabilidad fisica y quimica del sulfato magnesico combinado con heparina sodica en solucion salina al 0,9 por 100. Farm Hosp 1995 ; 19: 38-40.
2108	noviny	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	noviny	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2212	Laboratoř	Reteplase (Rapilysin®) - Summary of Product Characteristics Actavis UK Ltd 2015
2221	noviny	Cober M.P, Johnson C.E. Stability of 70% alcohol solutions in polypropylene syringes for use in ethanol-lock therapy. Am J Health-Syst Pharm 2007 ; 64, 23: 2480-2482.
2233	noviny	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	noviny	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	noviny	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	noviny	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2271	Laboratoř	Daptomycine (Cubicin®) Résumé des caractéristiques du produits Novartis 2006
2279	noviny	Kupiec T, Trusley C, Ben M, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759.
2335	noviny	Canann D, Tyler L.S, Barker B, Condie C. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
2346	noviny	Newland A.M, Mauro V.F, Alexander K.S. Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents Am J Health-Syst Pharm 2009 ; 66: 986-987.
2375	noviny	Strong DK, Ho W, Nairn JG. Visual compatibility of vancomycin and heparin in peritoneal dialysis solutions Am J Hosp Pharm 1989 ; 46: 1832 - 1833.
3012	noviny	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3125	noviny	Baker D S, Waldrop Bruce, Arnold John. Compatibility and Stability of Cefotaxine, Vancomycin, and Ciprofloxacin in Antibiotic Lock Solutions Containing Heparin. Int J Pharm Compound 2010 ; 14, 4: 346-349.
3134	noviny	Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ; 21: 96-103.
3152	noviny	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3176	plakát	Humbert Delaloye V, Berger M, Voirol P, Pannatier A. Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté. 16èmes JFSPH, Sion, 18-19 novembre 2010
3184	Laboratoř	Hyaluronidase (Hyalase®) - Summary of Product characteristics. CP Pharmaceuticals 2005
3210	noviny	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.
3212	noviny	Ribas Nicolau, B.; P?rez Juan, E.; Amor?s Cerd?, S.M.; Ar?valo Rubert, M.J.; Maqueda Palau, M. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos. Enferm Intensiva 2011 ;22:78-82.
3216	noviny	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	noviny	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	noviny	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3267	Laboratoř	Lipomed Laboratories Dacarbazine Lipomed - Summary of Product Characteristics Lipomed 2011
3294	noviny	Humbert-Delaloye V, Berger M, Voirol P, Pannatier A. In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs EJHP 2012 ; 19: 57-64.
3327	noviny	LaPlante K.L, Woodmansee S, Mermel L.A. Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions. Am J Health-Syst Pharm 2012 ; 69:1405-1409
3372	noviny	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3408	noviny	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3463	noviny	Eva Perez Juan, Maria Jos? Arévalo Rubert , Silvia Monica Amoros Cerda , Palau M.M, Nicolau B.R. Fármacos en perfusión continua en la unidad de cuidados intensivos: estudio de compatibilidad. Nursing 2011 ; 29 :62-6
3464	noviny	Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amoros-Cerda, Bàrbara Ribas-Nicolau. Compatibilidad física de la amiodarona en perfusión continua Enferm Clin 2011 21:25-29.
3465	noviny	E. P?rez Juan, M. Maqueda Palau, M. Ar?valo Rubert, B. Ribas Nicolau, S.M. Amor?s Cerd?. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ;21:96-103.
3466	noviny	B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos Enferm Intensiva 2011 ;22:78-82.
3520	Laboratoř	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3525	Laboratoř	Pethidine hydrochloride - Summary of product Characteristics AMCO Amdipharm Mercury 2012
3529	Laboratoř	Ciprofloxacin – Summary of Product Characteristics Hospira 2013
3531	Laboratoř	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3540	Laboratoř	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3548	Laboratoř	Cefepime (Maxipime®) - Summary of Product caracteristics. Bristol Myers Squibb 2007
3549	Laboratoř	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3562	Laboratoř	Ofloxacin (Tarivid®) - Summary of Product Characteristics Sanofi 2014
3577	Laboratoř	Daunorubicine (Daunoxome®) - Résumé des caractéristiques du produit Galen Limited
3580	Laboratoř	Cytarabine Accord - Résumé des caractéristiques du produit Accord Healthcare France 2016
3588	Laboratoř	Vancomycine (Vancocin®) - Résumé des caractéristiques du produit Sandoz 2011
3604	Laboratoř	Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit Sanofi Aventis France 2012
3605	Laboratoř	Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit Lipomed 2010
3616	Laboratoř	Altéplase (Actilyse®) - Résumé des caractéristiques du produit Boehringer Ingelheim 2012
3617	Laboratoř	Hyaluronidase (Hyalase®) - Summary of Product Characteristics Wockhardt 2011
3632	Laboratoř	Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics Hospira 2017
3637	Laboratoř	Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hameln Pharmaceuticals 2014
3640	Laboratoř	Mitoxantrone - Summary of Product Characteristics Hospira 2013
3643	Laboratoř	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3645	Laboratoř	Doxorubicin - Summary of Product Characteristics Accord Healthcare 2014
3665	noviny	Ortega R, Salmer?n-Garc?a A, Cabeza J, Capit?n-Vallvey L.F, Navas N. Stability of daptomycin 5 mg/mL and heparin sodium 100 units/mL combined in lactated Ringer’s injection and stored in polypropylene syringes at 4 and -20°C. Am J Health-Syst Pharm 2014 ; 71:956-959
3674	Laboratoř	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3687	Laboratoř	Cefuroxime sodium - Summary of Product Characteristics Stravencon 2013
3728	noviny	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766	noviny	Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	noviny	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3781	noviny	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide. EJHP 2015 ;22:1 56-58
3823	noviny	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l’unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3824	noviny	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	plakát	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	plakát	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	plakát	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3920	Laboratoř	Levofloxacine - Résumé Caractéristique du Produit Fresenius Kabi 2018
3923	noviny	Luu Y, Thigpen J, Brown S.D. Stability of sildenafil in combination with heparin and dopamine. Am J Health-Syst Pharm 2017 ; 74, 1: e64-e71
3934	Laboratoř	Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016
3956	noviny	Bastani B; Amin K; Herr A. Prolonged Stability of Stored Vancomycin, Gentamicin, and Heparin for Use in the Antibiotic-Lock Technique. ASAIO Journal 2005 ; 51,6:761-763.
3958	noviny	Henrickson K.J; . Powell K.R; . Schwartz C.L. A Dilute Solution of Vancomycin and Heparin Retains Antibacterial and Anticoagulant Activities . J Infect Dis 1988 ; 157, 3: 600-601.
3964	noviny	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3976	noviny	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055	noviny	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4056	noviny	Kandel S, Zaidi S, Wanandy T, Ming L, Castelino R, Sud K, Patel R. Stability of ceftazidime and heparine in four different types of peritoneal dialysis solutions. Perit Dial Int 2017
4108	noviny	Cruz K, Chrchwell M, Mauro V, Boddu. Physical compatibility of levetiracetam injection with heparin, dobutamine, and dopamine. Am J Health-Syst Pharm 2018 ;75;8:510-512
4145	noviny	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4166	noviny	Bowie H.M, Haylor V. Stability of heparin in sodium chloride solution. J Clin Pharm Ther 1978 3:211-214
4180	noviny	Mendes K, Harmanjeet H, Sedeeq M, Modi A, Wanandy T, Zaidi S, Ming L, Castelino R, Sud K, Peterson G, Patel R. Stability of meropenem and piperacillin/tazobactam with heparin in various peritoneal dialysis solutions. Perit Dial Int 2018 ;38,6:430-440
4254	noviny	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4319	noviny	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4332	plakát	Compatibilité de Glycophos® avec d’autres médicaments administrés en perfusion aux soins intensifs (SI) Compatibilité de Glycophos® avec d’autres médicaments administrés en perfusion aux soins intensifs (SI). JFSPH 2019 2019
4389	noviny	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4419	noviny	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4433	noviny	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	noviny	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4491	noviny	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2020
4507	noviny	Ross E, Salinas A, Petty K, Her C, Carpenter J. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing. Am J Health-Syst Pharm 2020 ;77,23:1980-1985
4528	noviny	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4538	noviny	Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397.
4556	noviny	Dobson, S.R, Mauro, V.F, Boddu, S.H.S, Churchwell, M.D. The Physical Compatibility of Clinically Used Concentrations of Diltiazem Hydrochloride With Heparin Sodium. J Pharm Technol 2020 ; 36, 4: 126-129.
4603	noviny	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4612	noviny	Villaba-Moreno AM, Gil-Navarro MV, Cotrina-Luque J, Pérez-Moreno MA, Chamorro-de Vega E. Estabilidad de la solución de gentamicina y heparina para sellado de catéter. OFIL 2014 24;2:86-90
4651	noviny	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176.
4654	plakát	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4698	noviny	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022
4724	noviny	Maktabi B, Howard MS, Baki G, Churchwell MD Intravenous Physical Compatibility of Heparin Sodium and Furosemide. Int J Pharm Compound 2022 ;26,6:522-526
4732	noviny	Kenneally A, Agbana P, Gardner B, Bae Y, Mitchell T, Beckman E. Compatibility of calcium chloride with milrinone, epinephrine, vasopressin, and heparin via in vitro testing and simulated Y-site administration. Am J Health-Syst Pharm 2023 80, 3;164–170
4742	noviny	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4768	noviny	Kondo M, Genpei M, Watanabe K, Yoshida M, Tagui N, Fukao S, Sugaya K, Takase H. Y-site injection physical compatibility of remdesivr with select intravenous drugs used in palliative care and for treating coronavirus disease 2019. Journal of Nippon Medical school 2023
4801	noviny	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4837	noviny	De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087.

Mentions Légales